Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Geron
Biotech
Gilead's accounting chief hits the exit—Chutes & Ladders
Gilead’s accounting chief hits the exit. Geron chief says goodbye. ITM preps for launch with leadership shake-up.
Darren Incorvaia
,
Zoey Becker
Mar 14, 2025 8:30am
Pfizer replaces retiring CSO with cancer chief—Chutes & Ladders
Nov 22, 2024 8:30am
Moderna, Terremoto, MEI Pharma and more—Chutes & Ladders
Jul 26, 2024 8:30am
Geron secures 12-2 AdComm vote in favor of blood cancer drug
Mar 15, 2024 5:00am
FDA questions benefit-risk profile of Geron's imetelstat
Mar 12, 2024 12:20pm
Geron eyes 2024 US launch for MDS drug after phase 3 win
Jan 4, 2023 10:45am